Showing 501 - 520 results of 60,129 for search '(( 5 ((we decrease) OR (teer decrease)) ) OR ( 50 ((a decrease) OR (nn decrease)) ))', query time: 1.26s Refine Results
  1. 501

    Image 1_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf by Francesca Bietto (21511316)

    Published 2025
    “…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
  2. 502

    Table 1_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.docx by Francesca Bietto (21511316)

    Published 2025
    “…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
  3. 503

    Image 4_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf by Francesca Bietto (21511316)

    Published 2025
    “…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
  4. 504

    Image 2_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf by Francesca Bietto (21511316)

    Published 2025
    “…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
  5. 505

    Image 3_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf by Francesca Bietto (21511316)

    Published 2025
    “…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
  6. 506
  7. 507
  8. 508
  9. 509
  10. 510
  11. 511

    Different Association of Human Papillomavirus 16 Variants with Early and Late Presentation of Cervical Cancer by Ana Alfaro (280118)

    Published 2016
    “…Remarkably, this risk was higher for ACC (OR = 6.0, 95% CI = 1.1–33, p < 0.05) than for SCC (OR = 2.8, 95% CI = 1.3–5.9, p < 0.01). Interestingly, when analyzing only the HPV16-positive CC, D2 increases (OR = 2.5, 95% CI = 1.2–5, p < 0.05) and D3 decreases (OR = 0.45, 95% CI 0.2–0.9, p < 0.05) the risk to develop CC before 50 years old in relation with A1/2 variant. …”
  12. 512
  13. 513
  14. 514
  15. 515
  16. 516
  17. 517
  18. 518
  19. 519
  20. 520